Netarsudil

CHICAGO — In this Healio Video Perspective from the AAO meeting, Osamah Saeedi, MD, discusses the effects of netarsudil on episcleral venous flow in subjects with ocular hypertension and glaucoma suspects.

In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery meeting via Zoom, Richard L. Lindstrom, MD, discusses the first prospective trial of netarsudil for the treatment of Fuchs’ dystrophy.

NASHVILLE, Tenn. — At the American Glaucoma Society meeting, Osamah Saeedi, MD, discusses results from a study exploring the effect of Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) on episcleral venous flow rates.

Netarsudil 0.02% appears to be more effective at lowering IOP in patients with open-angle glaucoma or ocular hypertension than ripasudil 0.4% in a phase 3 clinical trial, according to a press release from Aerie Pharmaceuticals.

Aerie Pharmaceuticals has completed enrollment in a phase 3 trial in Japan investigating netarsudil in patients with primary open-angle glaucoma or ocular hypertension, according to a press release.

Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.

The European Commission has granted marketing authorization for Roclanda to reduce IOP in adults with primary open-angle glaucoma or ocular hypertension, according to a press release from Aerie Pharmaceuticals.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Roclanda, according to a press release from Aerie Pharmaceuticals.

The addition of netarsudil as an adjunctive treatment yielded further IOP lowering in patients with glaucoma enrolled in a phase 4 study.

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thomas A. Mitro, president and chief operating officer of Aerie Pharmaceuticals, updates the company’s progress with Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), and discusses receiving the Glaucoma Research Foundation’s Catalyst Award.